Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
01. Dezember 2021 16:05 ET
|
Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...